WebOverview: Exosomes and other extracellular vesicles (EVs) have emerged as an immensely versatile source of biomarkers for molecular diagnostics, enabling and enhancing the field of liquid biopsy, from mutation detection to RNA profiling and/or protein analysis. The field of liquid biopsy and EV based diagnostics has made substantial progress ... WebJun 26, 2024 · Bio-Techne Corporation announced Tuesday its second acquisition of the month. The Minneapolis-based company reached a deal to acquire Exosome …
Brandon Hanna - Commercial Director C> Senior …
WebApr 10, 2024 · Exosome Diagnostics is a liquid biopsy company that harness the power of Exosomes as a multi-analyte component of Liquid Biopsies. Bio-Techne, and all of its … WebJun 26, 2024 · Bio-Techne has agreed to acquire Exosome Diagnostics for up to $575 million, in a deal intended to position the buyer as a leader in non-invasive liquid biopsies and a developer of diagnostics for chimeric antigen receptor T cell (CAR-T) cancer therapies. Headquartered in Waltham, MA, Exosome Diagnostics is a developer of … danish interior design pastel
Exosomes Extracellular vesicles - EVs QIAGEN
Web1 day ago · An exosome-based ESR1 monitoring RT-qPCR technology that rapidly and accurately detects circulating tumor acquired resistance variants at ≤0.1% frequency in liquid biopsy samples Tuesday, April 18 th from 9:00 AM – 12:30 PM EDT Presenter: Gary Latham, Ph. D. Section 37, Poster Board #29, Abstract #4354 WebExosome (Bio-Techne) Feb 2024 - Present4 years 3 months. Waltham, MA. My responsibilities are to provide support for all end user hardware … WebTimothy Sampson, PhD. Dr. Sampson’s research focuses on host-microbe interactions at the interface of Parkinson’s disease, Alzheimer’s disease, and other neurological illnesses. His work aims to reveal new pathways at the microbiota-brain axis. Read the interview. birthday cake with mice